

616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Targeted and Immune-based Approaches in the Treatment of AML

[811](#)

[Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial](#)

Lihua Budde, MD, PhD¹, Joo Y Song, MD^{1*}, Young Kim, MD^{1*}, Suzette Blanchard, PhD^{1*}, et al.

The authors of the study conclude that:

In this first-in-human clinical trial of CD123CAR T cell therapy, we have demonstrated the feasibility and safety of targeting CD123. We have also observed promising anti-leukemic activity in both AML and BPDCN. Importantly, no myeloablative effects have been observed, supporting further testing of this immunotherapeutic strategy in both transplant eligible and ineligible patients.

[812](#)

[Targeting the Transcriptional Addiction of Leukemia Stem Cells By a New Class of Protein Kinase Inhibitors](#)

Yinon Ben-Neriah, MD, PhD^{1*}, Avanthika Venkatachalam, MSc^{1*}, Avner Fink, PhD^{1*}, Eric Hung,

MSc^{1*}, J et al.

The authors of the study conclude that:

We developed a new class of small molecule inhibitors that co-targets CKI α and P-TEFb. These inhibitors have unique pharmacologic properties: short-term kinase inhibition results in long-term disruption of SE activity. Shutdown of leukemic super-enhancers in synergy with robust p53 activation compromises leukemic cells and stem cells addicted to SE-driven transcription. These features explain the powerful and specific anti-leukemic therapeutic effects of this new class of inhibitors in-vivo.

[813](#)

[Preliminary Results from a Phase Ib Study Evaluating BCL-2 Inhibitor Venetoclax in Combination with MEK Inhibitor Cobimetinib or MDM2 Inhibitor Idasanutlin in Patients with Relapsed or Refractory \(R/R\) AML](#)

Naval Daver, MD¹, Daniel A. Pollyea, MD^{2,3}, Karen W.L. Yee, MD^{4*}, Pierre Fenaux, MD, PhD⁵, et al.

The authors of the study conclude that:

Preliminary results show that VEN plus cobimetinib or idasanutlin can be administered with appropriate risk mitigation measures for GI toxicity and early evidence of clinical activity in R/R AML pts. Dose finding is ongoing and the MTD for both combinations has not yet been determined. Preliminary ORR for the VEN 600 mg + idasanutlin 200 mg cohort was encouraging at 38%. Safety, PK and efficacy data will be updated at the time of presentation.

[814](#)

[TAK-243 Is a Selective UBA1 Inhibitor That Displays Preclinical Activity in Acute Myeloid Leukemia \(AML\)](#)

Samir H. Barghout, BSPHarm, MSc^{1,2}, Parasvi Patel, BSc (Hons)^{1,2*}, Xiaoming Wang^{1*}, G. Wei Xu^{1*}, S et al.

The authors of the study conclude that:

TAK-243 is a potent and selective UBA1 inhibitor that displays preferential activity towards AML cells over normal hematopoietic cells. Acquired mutations affect drug binding and may be a clinically relevant mechanism of resistance. These data support conducting a clinical trial of TAK-243 in patients with AML.

[815](#)

[Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia](#)

Farhad Ravandi, MBBS¹, Naval Daver, MD², Guillermo Garcia-Manero, MD², Christopher B Benton, MD³, et al.

The authors of the study conclude that:

Addition of nivolumab to ara-C and anthracycline induction chemotherapy is feasible and safe in younger pts with AML. Among the pts proceeding to alloSCT the risk of GVHD is not significantly increased.

[816](#)

[Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML](#)

Geoffrey L. Uy, MD¹, Michael P Rettig, PhD¹, Theresa Fletcher^{1*}, Peter A Riedell, MD², et al.

The authors of the study conclude that:

That selinexor + CLAG is highly active in patients with relapsed or refractory AML and has encouraging rates of CR. Furthermore, the combination serves as a bridge which allows a high percentage of patients to undergo allogeneic hematopoietic cell transplantation.